Welcome back to the Real Life Pharmacology podcast.

Today I'm going to cover the SGLT2 inhibitors.

This is a class of medication that is used in the management of diabetes.

And these drugs do not act on insulin.

So that is a nice advantage.

Obviously, we're going to have pretty low risk for any type of hypoglycemia or anything of that nature.

But a few examples of medications within this class,

Empagliflozine, brand name Jardience,

Dappa Glyphlozen, Farksiga,

and cana glyphlozin or invocana.

So kind of hard to pronounce,

but remember the glyphlozin ending,

and that should help you remember that these drugs fall in the SGLLT2 inhibitor class.

So let's talk about the mechanism of action a little bit.

SGLT2, so sodium glucose co-transporter 2 and by these drugs inhibiting that transporter what happens is it prevents the reabsorption of glucose back into the body so really in the kidney it prevents glucose reabsorption back into the body.

So when we think about this, what happens to the glucose? It goes out through the urine.

Now, that can lead to some potential issues, which we'll certainly talk about inside effects,

but definitely wanted to cover that

mechanism of action.

And that's why I said when it doesn't really mess with insulin, that's definitely a potential

advantage.

One other thing with not stimulating insulin release or not injecting exogenous insulin is we don't need to worry about

...